Under the selective pressure of first- and third-generation EGFR-TKIs, tumor cells can adapt through on-target alterations (for example, T790M or C797S), as well as via bypass-track activation, such as MET amplification, HER2 or AXL upregulation, and reactivation of downstream signaling. The gene discussed is MET; the disease is neoplasm.